acinetobacter baumannii

Summary

Summary: A species of gram-negative, aerobic bacteria, commonly found in the clinical laboratory, and frequently resistant to common antibiotics.

Top Publications

  1. Michalopoulos A, Falagas M, Karatza D, Alexandropoulou P, Papadakis E, Gregorakos L, et al. Epidemiologic, clinical characteristics, and risk factors for adverse outcome in multiresistant gram-negative primary bacteremia of critically ill patients. Am J Infect Control. 2011;39:396-400 pubmed publisher
    ..Fifty monomicrobial episodes of primary bacteremia because of Klebsiella pneumoniae (n = 20), Acinetobacter baumannii (n = 18), and Pseudomonas aeruginosa (n = 12) were recorded...
  2. Nakazawa Y, Ii R, Tamura T, Hoshina T, Tamura K, Kawano S, et al. A case of NDM-1-producing Acinetobacter baumannii transferred from India to Japan. J Infect Chemother. 2013;19:330-2 pubmed publisher
    ..Multidrug-resistant Acinetobacter baumannii was isolated from his sputum...
  3. Consales G, Gramigni E, Zamidei L, Bettocchi D, De Gaudio A. A multidrug-resistant Acinetobacter baumannii outbreak in intensive care unit: antimicrobial and organizational strategies. J Crit Care. 2011;26:453-459 pubmed publisher
    Multidrug-resistant Acinetobacter baumannii (MRAB) is an emerging cause of intensive care unit (ICU) outbreaks. Patients are the main reservoirs, inducing cross transmission...
  4. Smani Y, McConnell M, Pachón J. Role of fibronectin in the adhesion of Acinetobacter baumannii to host cells. PLoS ONE. 2012;7:e33073 pubmed publisher
    Adhesion to host cells is an initial and important step in Acinetobacter baumannii pathogenesis. However, there is relatively little information on the mechanisms by which A. baumannii binds to and interacts with host cells...
  5. Hwang Y, Ramalingam K, Bienek D, Lee V, You T, Alvarez R. Antimicrobial activity of nanoemulsion in combination with cetylpyridinium chloride in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2013;57:3568-75 pubmed publisher
    b>Acinetobacter baumannii has emerged as a serious problematic pathogen due to the ever-increasing presence of antibiotic resistance, demonstrating a need for novel, broad-spectrum antimicrobial therapeutic options...
  6. Hraiech S, Roch A, Lepidi H, Atieh T, Audoly G, Rolain J, et al. Impaired virulence and fitness of a colistin-resistant clinical isolate of Acinetobacter baumannii in a rat model of pneumonia. Antimicrob Agents Chemother. 2013;57:5120-1 pubmed publisher
    We compared the fitness and lung pathogenicity of two isogenic clinical isolates of Acinetobacter baumannii, one resistant (ABCR) and the other susceptible (ABCS) to colistin. In vitro, ABCR exhibited slower growth kinetics than ABCS...
  7. Chu H, Zhao L, Wang M, Liu Y, Gui T, Zhang J. Sulbactam-based therapy for Acinetobacter baumannii infection: a systematic review and meta-analysis. Braz J Infect Dis. 2013;17:389-94 pubmed publisher
    A number of studies have reported on the effectiveness of sulbactam-based therapies for Acinetobacter baumannii infection; however, there is little evidence that sulbactam-based therapies are more or less effective than alternative ..
  8. Smith C, Antunes N, Stewart N, Toth M, Kumarasiri M, Chang M, et al. Structural basis for carbapenemase activity of the OXA-23 ?-lactamase from Acinetobacter baumannii. Chem Biol. 2013;20:1107-15 pubmed publisher
    Dissemination of Acinetobacter baumannii strains harboring class D ?-lactamases producing resistance to carbapenem antibiotics severely limits our ability to treat deadly Acinetobacter infections. Susceptibility determination in the A...
  9. Huang G, Le S, Peng Y, Zhao Y, Yin S, Zhang L, et al. Characterization and genome sequencing of phage Abp1, a new phiKMV-like virus infecting multidrug-resistant Acinetobacter baumannii. Curr Microbiol. 2013;66:535-43 pubmed publisher
    While screening for alternative antibiotics against multidrug-resistant Acinetobacter baumannii, we isolated a virulent A. baumannii bacteriophage Abp1...

More Information

Publications83

  1. Yoon E, Courvalin P, Grillot Courvalin C. RND-type efflux pumps in multidrug-resistant clinical isolates of Acinetobacter baumannii: major role for AdeABC overexpression and AdeRS mutations. Antimicrob Agents Chemother. 2013;57:2989-95 pubmed publisher
    ..division (RND)-type efflux systems plays a major role in the multidrug resistance (MDR) of Acinetobacter baumannii. However, the relative contributions of the three most prevalent pumps, AdeABC, AdeFGH, and AdeIJK, have ..
  2. Munoz Price L, Fajardo Aquino Y, Arheart K, Cleary T, Depascale D, Pizano L, et al. Aerosolization of Acinetobacter baumannii in a trauma ICU*. Crit Care Med. 2013;41:1915-8 pubmed publisher
    To establish the presence of air contamination with Acinetobacter baumannii in the trauma ICU. Point prevalence microbiological surveillances. A 1,500-bed public teaching hospital in the Miami metro area. Trauma ICU patients...
  3. Jurenaite M, Markuckas A, Suziedeliene E. Identification and characterization of type II toxin-antitoxin systems in the opportunistic pathogen Acinetobacter baumannii. J Bacteriol. 2013;195:3165-72 pubmed publisher
    b>Acinetobacter baumannii is an opportunistic pathogen that causes nosocomial infections. Due to the ability to persist in the clinical environment and rapidly acquire antibiotic resistance, multidrug-resistant A...
  4. Bakour S, Touati A, Sahli F, Ameur A, Haouchine D, Rolain J. Antibiotic resistance determinants of multidrug-resistant Acinetobacter baumannii clinical isolates in Algeria. Diagn Microbiol Infect Dis. 2013;76:529-31 pubmed publisher
    Antibiotic susceptibility testing was performed on 71 Acinetobacter baumannii clinical isolates, and presence of antibiotic resistance genes was screened for by PCR amplification and sequencing...
  5. Cetin E, Tekeli A, Ozseven A, Us E, Aridogan B. Determination of in vitro activities of polymyxin B and rifampin in combination with ampicillin/sulbactam or cefoperazone/sulbactam against multidrug-resistant Acinetobacter baumannii by the E-test and checkerboard methods. Jpn J Infect Dis. 2013;66:463-8 pubmed
    ..combination with ampicillin/sulbactam (AS) or cefoperazone/sulbactam (CS) against 20 multidrug-resistant Acinetobacter baumannii (MDR-AB) isolates by the checkerboard and E-test methods...
  6. Miyasaki Y, Rabenstein J, Rhea J, Crouch M, Mocek U, Kittell P, et al. Isolation and characterization of antimicrobial compounds in plant extracts against multidrug-resistant Acinetobacter baumannii. PLoS ONE. 2013;8:e61594 pubmed publisher
    The number of fully active antibiotic options that treat nosocomial infections due to multidrug-resistant Acinetobacter baumannii (A. baumannii) is extremely limited...
  7. Durante Mangoni E, Signoriello G, Andini R, Mattei A, De Cristoforo M, Murino P, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013;57:349-58 pubmed publisher
    Extensively drug-resistant (XDR) Acinetobacter baumannii may cause serious infections in critically ill patients. Colistin often remains the only therapeutic option. Addition of rifampicin to colistin may be synergistic in vitro...
  8. Liu C, Tang C, Kuo H, Lu C, Chang K, Liou M. The origin of Acinetobacter baumannii TYTH-1: a comparative genomics study. Int J Antimicrob Agents. 2013;41:318-24 pubmed publisher
    There have been increasing reports of bla(OXA-23)-carrying strains of carbapenem-resistant Acinetobacter baumannii (CRAB), which has become a significant public health concern in Taiwan...
  9. Lee Y, Tsao S, Hsueh P. Clinical outcomes of tigecycline alone or in combination with other antimicrobial agents for the treatment of patients with healthcare-associated multidrug-resistant Acinetobacter baumannii infections. Eur J Clin Microbiol Infect Dis. 2013;32:1211-20 pubmed publisher
    Tigecycline (TG) has been shown to be active in vitro against Acinetobacter baumannii, although data on the clinical efficacy of TG alone or in combination for the treatment of infections due to multidrug-resistant A...
  10. Zimbler D, Arivett B, Beckett A, Menke S, Actis L. Functional features of TonB energy transduction systems of Acinetobacter baumannii. Infect Immun. 2013;81:3382-94 pubmed publisher
    b>Acinetobacter baumannii is an opportunistic pathogen that causes severe nosocomial infections. Strain ATCC 19606(T) utilizes the siderophore acinetobactin to acquire iron under iron-limiting conditions encountered in the host...
  11. Sahl J, Gillece J, Schupp J, Waddell V, Driebe E, Engelthaler D, et al. Evolution of a pathogen: a comparative genomics analysis identifies a genetic pathway to pathogenesis in Acinetobacter. PLoS ONE. 2013;8:e54287 pubmed publisher
    b>Acinetobacter baumannii is an emergent and global nosocomial pathogen. In addition to A...
  12. Pelletier M, Casella L, Jones J, Adams M, Zurawski D, Hazlett K, et al. Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother. 2013;57:4831-40 pubmed publisher
    b>Acinetobacter baumannii is a nosocomial opportunistic pathogen that can cause severe infections, including hospital-acquired pneumonia, wound infections, and sepsis...
  13. Harris G, Kuo Lee R, Lam C, Kanzaki G, Patel G, Xu H, et al. A mouse model of Acinetobacter baumannii-associated pneumonia using a clinically isolated hypervirulent strain. Antimicrob Agents Chemother. 2013;57:3601-13 pubmed publisher
    b>Acinetobacter baumannii is an important emerging pathogen in health care-acquired infections and is responsible for severe nosocomial and community-acquired pneumonia. Currently available mouse models of A...
  14. Rumbo C, Gato E, Lopez M, Ruiz de Alegria C, Fernandez Cuenca F, Martinez Martinez L, et al. Contribution of efflux pumps, porins, and ?-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2013;57:5247-57 pubmed publisher
    ..aminoglycosides, glycylcyclines, tetracyclines, and quinolones in 90 multiresistant clinical strains of Acinetobacter baumannii isolated from two genetically unrelated A...
  15. Kenyon J, Hall R. Variation in the complex carbohydrate biosynthesis loci of Acinetobacter baumannii genomes. PLoS ONE. 2013;8:e62160 pubmed publisher
    ..This indicates that this region is being substituted repeatedly in multiply antibiotic resistant isolates from these clones...
  16. Smani Y, Domínguez Herrera J, Pachón J. Association of the outer membrane protein Omp33 with fitness and virulence of Acinetobacter baumannii. J Infect Dis. 2013;208:1561-70 pubmed publisher
    Outer membrane protein 33 (Omp33) is an outer membrane porin of Acinetobacter baumannii associated with carbapenem resistance. However, the role of Omp33 in the fitness and virulence of A. baumannii remains unknown...
  17. Shields R, Clancy C, Gillis L, Kwak E, Silveira F, Massih R, et al. Epidemiology, clinical characteristics and outcomes of extensively drug-resistant Acinetobacter baumannii infections among solid organ transplant recipients. PLoS ONE. 2012;7:e52349 pubmed publisher
    Extensively drug-resistant Acinetobacter baumannii (XDR-Ab) has emerged as a major nosocomial pathogen, but optimal treatment regimens are unknown...
  18. Alsultan A, Evans B, Elsayed E, Al Thawadi S, Al Taher A, Amyes S, et al. High frequency of carbapenem-resistant Acinetobacter baumannii in patients with diabetes mellitus in Saudi Arabia. J Med Microbiol. 2013;62:885-8 pubmed publisher
    Carbapenem-resistant Acinetobacter baumannii is becoming increasingly prevalent in patients with diabetes mellitus in the Middle East...
  19. Pogue J, Mann T, Barber K, Kaye K. Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management. Expert Rev Anti Infect Ther. 2013;11:383-93 pubmed publisher
    Carbapenem-resistant Acinetobacter baumannii pose a significant threat to hospitalized patients, as therapeutic options are scarse. Alarmingly, rates of carbapenem-resistance in A...
  20. Manepalli S, Gandhi J, Ekhar V, Asplund M, Coelho C, Martinez L. Characterization of a cyclophosphamide-induced murine model of immunosuppression to study Acinetobacter baumannii pathogenesis. J Med Microbiol. 2013;62:1747-54 pubmed publisher
    b>Acinetobacter baumannii is a Gram-negative bacterium that opportunistically infects critically ill hospitalized patients with breaches in skin integrity and airway protection, leading to significant morbidity and mortality...
  21. Bonnin R, Nordmann P, Poirel L. Screening and deciphering antibiotic resistance in Acinetobacter baumannii: a state of the art. Expert Rev Anti Infect Ther. 2013;11:571-83 pubmed publisher
    b>Acinetobacter baumannii, recognized as a serious threat in healthcare facilities, has the ability to develop resistance to antibiotics quite easily...
  22. Chopra S, Ramkissoon K, Anderson D. A systematic quantitative proteomic examination of multidrug resistance in Acinetobacter baumannii. J Proteomics. 2013;84:17-39 pubmed publisher
    Multidrug-resistant Acinetobacter baumannii strains have been examined at the DNA sequence level, but seldom using large-scale quantitative proteomics...
  23. Sousa D, Castelo Corral L, Gutiérrez Urbón J, Molina F, López Calviño B, Bou G, et al. Impact of ertapenem use on Pseudomonas aeruginosa and Acinetobacter baumannii imipenem susceptibility rates: collateral damage or positive effect on hospital ecology?. J Antimicrob Chemother. 2013;68:1917-25 pubmed publisher
    Conflicting evidence has been reported on the impact of ertapenem use on the susceptibility of Pseudomonas spp. to group 2 carbapenems. No extensive data for Acinetobacter baumannii are currently available.
  24. Sonnevend A, Ghazawi A, Al Munthari N, Pitout M, Hamadeh M, Hashmey R, et al. Characteristics of epidemic and sporadic strains of Acinetobacter baumannii isolated in Abu Dhabi hospitals. J Med Microbiol. 2013;62:582-90 pubmed publisher
    We compared the antibiotic susceptibility, clonal lineages and resistance genes of singleton Acinetobacter baumannii strains to those of isolates representing repeatedly encountered molecular types in five Abu Dhabi hospitals...
  25. Eijkelkamp B, Stroeher U, Hassan K, Elbourne L, Paulsen I, Brown M. H-NS plays a role in expression of Acinetobacter baumannii virulence features. Infect Immun. 2013;81:2574-83 pubmed publisher
    b>Acinetobacter baumannii has become a major problem in the clinical setting with the prevalence of infections caused by multidrug-resistant strains on the increase...
  26. Revathi G, Siu L, Lu P, Huang L. First report of NDM-1-producing Acinetobacter baumannii in East Africa. Int J Infect Dis. 2013;17:e1255-8 pubmed publisher
    The emergence of carbapenem-resistant Acinetobacter baumannii (CRAB) was observed in a Kenyan hospital from 2009 to 2010...
  27. Ntusi N, Badri M, Khalfey H, Whitelaw A, Oliver S, Piercy J, et al. ICU-associated Acinetobacter baumannii colonisation/infection in a high HIV-prevalence resource-poor setting. PLoS ONE. 2012;7:e52452 pubmed publisher
    ..There are hardly any data about the incidence, risk factors and outcomes of ICU-associated A.baumannii colonisation/infection in HIV-infected and uninfected persons from resource-poor settings like Africa...
  28. Lesho E, Yoon E, McGann P, Snesrud E, Kwak Y, Milillo M, et al. Emergence of colistin-resistance in extremely drug-resistant Acinetobacter baumannii containing a novel pmrCAB operon during colistin therapy of wound infections. J Infect Dis. 2013;208:1142-51 pubmed publisher
    ..Colistin resistance is of concern since it is increasingly needed to treat infections caused by bacteria resistant to all other antibiotics and has been associated with poorer outcomes. Longitudinal data from in vivo series are sparse...
  29. Koning R, de Breij A, Oostergetel G, Nibbering P, Koster A, Dijkshoorn L. Cryo-electron tomography analysis of membrane vesicles from Acinetobacter baumannii ATCC19606 T. Res Microbiol. 2013;164:397-405 pubmed publisher
    b>Acinetobacter baumannii is an important nosocomial pathogen responsible for colonization and infection of critically ill patients. Its virulence attributes together with the condition of the host determine the pathogenicity of A...
  30. King L, Pangburn M, McDaniel L. Serine protease PKF of Acinetobacter baumannii results in serum resistance and suppression of biofilm formation. J Infect Dis. 2013;207:1128-34 pubmed publisher
    b>Acinetobacter baumannii is an important nosocomial pathogen...
  31. Amin I, Richmond G, Sen P, Koh T, Piddock L, Chua K. A method for generating marker-less gene deletions in multidrug-resistant Acinetobacter baumannii. BMC Microbiol. 2013;13:158 pubmed publisher
    b>Acinetobacter baumannii is an important nosocomial pathogen that has become increasingly resistant to multiple antibiotics. Genetic manipulation of MDR A...
  32. Higgins P, Pérez Llarena F, Zander E, Fernandez A, Bou G, Seifert H. OXA-235, a novel class D ?-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother. 2013;57:2121-6 pubmed publisher
    We investigated the mechanism of carbapenem resistance in 10 Acinetobacter baumannii strains isolated from the United States and Mexico between 2005 and 2009...
  33. Wilharm G, Piesker J, Laue M, Skiebe E. DNA uptake by the nosocomial pathogen Acinetobacter baumannii occurs during movement along wet surfaces. J Bacteriol. 2013;195:4146-53 pubmed publisher
    The emergence of Acinetobacter baumannii as an increasingly multidrug-resistant nosocomial pathogen largely relies on acquisition of resistance genes via horizontal gene transfer. Here, we demonstrate that many clinical isolates of A...
  34. Karaoglan I, Zer Y, Boşnak V, Mete A, Namiduru M. In vitro synergistic activity of colistin with tigecycline or ?-lactam antibiotic/?-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii. J Int Med Res. 2013;41:1830-7 pubmed publisher
    Nosocomial infection caused by carbapenem-resistant Acinetobacter baumannii is a worldwide problem and treatment options remain controversial...
  35. Asplund M, Coelho C, Cordero R, Martinez L. Alcohol impairs J774.16 macrophage-like cell antimicrobial functions in Acinetobacter baumannii infection. Virulence. 2013;4:467-72 pubmed publisher
    b>Acinetobacter baumannii (Ab) is a common cause of community-acquired pneumonia (CAP) in chronic alcoholics in tropical and sub-tropical climates and associated with a > 50% mortality rate. We demonstrated that exposure of J774...
  36. Hamidian M, Hall R. Tn6168, a transposon carrying an ISAba1-activated ampC gene and conferring cephalosporin resistance in Acinetobacter baumannii. J Antimicrob Chemother. 2014;69:77-80 pubmed publisher
    To explore the cause of third-generation cephalosporin resistance in Australian Acinetobacter baumannii isolates belonging to global clone 1 (GC1).
  37. Aranda J, Poza M, Shingu Vazquez M, Cortés P, Boyce J, Adler B, et al. Identification of a DNA-damage-inducible regulon in Acinetobacter baumannii. J Bacteriol. 2013;195:5577-82 pubmed publisher
    The transcriptional response of Acinetobacter baumannii, a major cause of nosocomial infections, to the DNA-damaging agent mitomycin C (MMC) was studied using DNA microarray technology...
  38. Ahmed Bentley J, Chandran A, Joffe A, French D, Peirano G, Pitout J. Gram-negative bacteria that produce carbapenemases causing death attributed to recent foreign hospitalization. Antimicrob Agents Chemother. 2013;57:3085-91 pubmed publisher
    ..Multiresistant Klebsiella pneumoniae, Escherichia coli, and Acinetobacter baumannii strains were isolated from a wound of a Canadian patient with a recent history of hospitalization in ..
  39. Abbott I, Cerqueira G, Bhuiyan S, Peleg A. Carbapenem resistance in Acinetobacter baumannii: laboratory challenges, mechanistic insights and therapeutic strategies. Expert Rev Anti Infect Ther. 2013;11:395-409 pubmed publisher
    ..In this article the authors discuss carbapenem resistance in Acinetobacter baumannii, a bacterial isolate often implicated in nosocomial infections...
  40. Norton M, Spilkia A, Godoy V. Antibiotic resistance acquired through a DNA damage-inducible response in Acinetobacter baumannii. J Bacteriol. 2013;195:1335-45 pubmed publisher
    b>Acinetobacter baumannii is an emerging nosocomial, opportunistic pathogen that survives desiccation and quickly acquires resistance to multiple antibiotics...
  41. Carruthers M, Nicholson P, Tracy E, Munson R. Acinetobacter baumannii utilizes a type VI secretion system for bacterial competition. PLoS ONE. 2013;8:e59388 pubmed publisher
    ..b>Acinetobacter baumannii is an opportunistic pathogen that causes severe infections in humans...
  42. Farrugia D, Elbourne L, Hassan K, Eijkelkamp B, Tetu S, Brown M, et al. The complete genome and phenome of a community-acquired Acinetobacter baumannii. PLoS ONE. 2013;8:e58628 pubmed publisher
    Many sequenced strains of Acinetobacter baumannii are established nosocomial pathogens capable of resistance to multiple antimicrobials. Community-acquired A. baumannii in contrast, comprise a minor proportion of all A...
  43. Richmond G, Chua K, Piddock L. Efflux in Acinetobacter baumannii can be determined by measuring accumulation of H33342 (bis-benzamide). J Antimicrob Chemother. 2013;68:1594-600 pubmed publisher
    Overexpression of efflux pumps in Acinetobacter baumannii is a common mechanism of multidrug resistance in this nosocomial pathogen...
  44. Zander E, Higgins P, Fernández González A, Seifert H. Detection of intrinsic blaOXA-51-like by multiplex PCR on its own is not reliable for the identification of Acinetobacter baumannii. Int J Med Microbiol. 2013;303:88-9 pubmed publisher
    ..baumannii when used without an additional independent method. Other species identification methods such as gyrB multiplex PCR and rpoB sequencing should be used to reliably identify A. baumannii...
  45. Stietz M, Ramirez M, Vilacoba E, Merkier A, Limansky A, Centron D, et al. Acinetobacter baumannii extensively drug resistant lineages in Buenos Aires hospitals differ from the international clones I-III. Infect Genet Evol. 2013;14:294-301 pubmed publisher
    As a way to contribute to the assessment of Acinetobacter baumannii clinical population structure, multi-locus sequence typing (MLST) was performed in a collection of 93 isolates from Buenos Aires (1983-2012) and Rosario (2006-2009) ..
  46. Feng X, Sambanthamoorthy K, Palys T, Paranavitana C. The human antimicrobial peptide LL-37 and its fragments possess both antimicrobial and antibiofilm activities against multidrug-resistant Acinetobacter baumannii. Peptides. 2013;49:131-7 pubmed publisher
    b>Acinetobacter baumannii infections are difficult to treat due to multidrug resistance. Biofilm formation by A. baumannii is an additional factor in its ability to resist antimicrobial therapy...
  47. Saroj S, Rather P. Streptomycin inhibits quorum sensing in Acinetobacter baumannii. Antimicrob Agents Chemother. 2013;57:1926-9 pubmed publisher
    Streptomycin at subinhibitory concentrations was found to inhibit quorum sensing in Acinetobacter baumannii. Conditioned medium prepared by growth of A...
  48. Fukuta Y, Muder R, Agha M, Clarke L, Wagener M, Hensler A, et al. Risk factors for acquisition of multidrug-resistant Acinetobacter baumannii among cancer patients. Am J Infect Control. 2013;41:1249-52 pubmed publisher
    Data regarding multidrug-resistant (MDR) Acinetobacter baumannii infections among cancer patients are limited.
  49. Giannouli M, Antunes L, Marchetti V, Triassi M, Visca P, Zarrilli R. Virulence-related traits of epidemic Acinetobacter baumannii strains belonging to the international clonal lineages I-III and to the emerging genotypes ST25 and ST78. BMC Infect Dis. 2013;13:282 pubmed publisher
    b>Acinetobacter baumannii is responsible for large epidemics in hospitals, where it can persist for long time on abiotic surfaces. This study investigated some virulence-related traits of epidemic A...
  50. Lin M, Liou M, Tu C, Yeh H, Lan C. Molecular epidemiology of integron-associated antimicrobial gene cassettes in the clinical isolates of Acinetobacter baumannii from northern Taiwan. Ann Lab Med. 2013;33:242-7 pubmed publisher
    ..aims of this study were to understand the molecular epidemiology of integron-associated gene cassettes in Acinetobacter baumannii across four hospitals in northern Taiwan and to clarify the relationship between the presence of ..
  51. Yamada Y, Suwabe A. Diverse carbapenem-resistance mechanisms in 16S rRNA methylase-producing Acinetobacter baumannii. J Med Microbiol. 2013;62:618-22 pubmed publisher
    Multidrug-resistant Acinetobacter baumannii has become a global problem. This study characterized amikacin-resistant A...
  52. Kaur N, Khokhar M, Jain V, Bharatam P, Sandhir R, Tewari R. Identification of druggable targets for Acinetobacter baumannii via subtractive genomics and plausible inhibitors for MurA and MurB. Appl Biochem Biotechnol. 2013;171:417-36 pubmed publisher
    ..was implemented to find a set of potential drug targets present in an opportunist bacterial pathogen, Acinetobacter baumannii (A. baumannii)...
  53. Snitkin E, Zelazny A, Gupta J, Palmore T, Murray P, Segre J. Genomic insights into the fate of colistin resistance and Acinetobacter baumannii during patient treatment. Genome Res. 2013;23:1155-62 pubmed publisher
    ..We performed WGS on longitudinal isolates of Acinetobacter baumannii from patients undergoing colistin treatment, and upon subsequent drug withdrawal...
  54. Rumbo Feal S, Gómez M, Gayoso C, Álvarez Fraga L, Cabral M, Aransay A, et al. Whole transcriptome analysis of Acinetobacter baumannii assessed by RNA-sequencing reveals different mRNA expression profiles in biofilm compared to planktonic cells. PLoS ONE. 2013;8:e72968 pubmed publisher
    ..The present work serves as a basis for future studies examining the complex network systems that regulate bacterial biofilm formation and maintenance. ..
  55. Goh H, Beatson S, Totsika M, Moriel D, Phan M, Szubert J, et al. Molecular analysis of the Acinetobacter baumannii biofilm-associated protein. Appl Environ Microbiol. 2013;79:6535-43 pubmed publisher
    b>Acinetobacter baumannii is a multidrug-resistant pathogen associated with hospital outbreaks of infection across the globe, particularly in the intensive care unit. The ability of A...
  56. Talreja D, Kaye K, Yu F, Walia S, Kumar A. Pathogenicity of ocular isolates of Acinetobacter baumannii in a mouse model of bacterial endophthalmitis. Invest Ophthalmol Vis Sci. 2014;55:2392-402 pubmed publisher
    To determine the virulence properties of ocular isolates of Acinetobacter baumannii in causing endophthalmitis in a mouse model.
  57. Bahador A, Taheri M, Pourakbari B, Hashemizadeh Z, Rostami H, Mansoori N, et al. Emergence of rifampicin, tigecycline, and colistin-resistant Acinetobacter baumannii in Iran; spreading of MDR strains of novel International Clone variants. Microb Drug Resist. 2013;19:397-406 pubmed publisher
    Multidrug-resistant Acinetobacter baumannii infections are serious challenges for clinicians because of A. baumannii propensity to acquire resistance to a wide spectrum of antimicrobial agents. In this study, 91 A...
  58. Lees Miller R, Iwashkiw J, Scott N, Seper A, Vinogradov E, Schild S, et al. A common pathway for O-linked protein-glycosylation and synthesis of capsule in Acinetobacter baumannii. Mol Microbiol. 2013;89:816-30 pubmed publisher
    Multi-drug resistant strains of Acinetobacter baumannii are increasingly being isolated in hospitals worldwide...
  59. Mishra S, Sen M, Upadhyay S, Bhattacharjee A. Genetic linkage of blaNDM among nosocomial isolates of Acinetobacter baumannii from a tertiary referral hospital in northern India. Int J Antimicrob Agents. 2013;41:452-6 pubmed publisher
    The aim of this study was to evaluate the emergence of blaNDM-1 among clinical isolates of Acinetobacter baumannii isolated from a north Indian tertiary care hospital and to assess the gene cassettes and resistance determinants located ..
  60. Weber B, Miyata S, Iwashkiw J, Mortensen B, Skaar E, Pukatzki S, et al. Genomic and functional analysis of the type VI secretion system in Acinetobacter. PLoS ONE. 2013;8:e55142 pubmed publisher
    ..These results suggest that the T6SS fulfils an important but as-yet-unidentified role in the various lifestyles of the Acinetobacter spp...
  61. Szejbach A, Mikucka A, Bogiel T, Gospodarek E. Usefulness of phenotypic and genotypic methods for metallo-beta-lactamases detection in carbapenem-resistant Acinetobacter baumannii strains. Med Sci Monit Basic Res. 2013;19:32-6 pubmed
    b>Acinetobacter baumannii is an opportunistic microorganism with an increasing role in nosocomial outbreaks. For the last 2 decades, a growing number of carbapenem-resistant A...
  62. Cao J, Song W, Gu B, Mei Y, Tang J, Meng L, et al. Correlation between carbapenem consumption and antimicrobial resistance rates of Acinetobacter baumannii in a university-affiliated hospital in China. J Clin Pharmacol. 2013;53:96-102 pubmed publisher
    To investigate the correlation between carbapenem consumption and rates of antimicrobial resistance in Acinetobacter baumannii, carbapenem consumption was expressed as defined daily dose based on the World Health Organization (WHO) ..
  63. Russo T, Beanan J, Olson R, Macdonald U, Cox A, St Michael F, et al. The K1 capsular polysaccharide from Acinetobacter baumannii is a potential therapeutic target via passive immunization. Infect Immun. 2013;81:915-22 pubmed publisher
    The emergence of extremely resistant and panresistant Gram-negative bacilli, such as Acinetobacter baumannii, requires consideration of nonantimicrobial therapeutic approaches...
  64. Nwugo C, Arivett B, Zimbler D, Gaddy J, Richards A, Actis L. Effect of ethanol on differential protein production and expression of potential virulence functions in the opportunistic pathogen Acinetobacter baumannii. PLoS ONE. 2012;7:e51936 pubmed publisher
    b>Acinetobacter baumannii persists in the medical environment and causes severe human nosocomial infections. Previous studies showed that low-level ethanol exposure increases the virulence of A. baumannii ATCC 17978...
  65. Mosqueda N, Espinal P, Cosgaya C, Viota S, Plasensia V, Alvarez Lerma F, et al. Globally expanding carbapenemase finally appears in Spain: nosocomial outbreak of acinetobacter baumannii producing plasmid-encoded OXA-23 in Barcelona, Spain. Antimicrob Agents Chemother. 2013;57:5155-7 pubmed publisher
    Resistance of Acinetobacter baumannii clinical isolates to carbapenems is on the rise worldwide mainly in association with the production of OXA-23. Until recently, however, OXA-23 was absent in Spain...
  66. Xu J, Sun Z, Li Y, Zhou Q. Surveillance and correlation of antibiotic consumption and resistance of Acinetobacter baumannii complex in a tertiary care hospital in northeast China, 2003-2011. Int J Environ Res Public Health. 2013;10:1462-73 pubmed publisher
    This study investigated the changes in resistance of Acinetobacter baumannii complex and the association of carbapenem-resistant A...
  67. Proschak A, Lubuta P, Grün P, Lohr F, Wilharm G, De Berardinis V, et al. Structure and biosynthesis of fimsbactins A-F, siderophores from Acinetobacter baumannii and Acinetobacter baylyi. Chembiochem. 2013;14:633-8 pubmed publisher
    Novel chatechol/hydroxamate siderophores (named "fimsbactins") were identified in Acinetobacter baumannii ATCC 17978 and Acinetobacter baylyi ADP1. The major compound, fimsbactin A, was isolated from low-iron cultures of A...
  68. Yeom J, Shin J, Yang J, Kim J, Hwang G. (1)H NMR-based metabolite profiling of planktonic and biofilm cells in Acinetobacter baumannii 1656-2. PLoS ONE. 2013;8:e57730 pubmed publisher
    b>Acinetobacter baumannii is an aerobic and gram-negative pathogenic bacterium that is resistant to most antibiotics. Recently, A. baumannii 1656-2 exhibited the ability to form biofilms under clinical conditions...
  69. Zhang Y, Zhu Y, Gupta A, Huang Y, Murray C, Vrahas M, et al. Antimicrobial blue light therapy for multidrug-resistant Acinetobacter baumannii infection in a mouse burn model: implications for prophylaxis and treatment of combat-related wound infections. J Infect Dis. 2014;209:1963-71 pubmed publisher
    In this study, we investigated the utility of antimicrobial blue light therapy for multidrug-resistant Acinetobacter baumannii infection in a mouse burn model. A bioluminescent clinical isolate of multidrug-resistant A...
  70. Ruan Z, Chen Y, Jiang Y, Zhou H, Zhou Z, Fu Y, et al. Wide distribution of CC92 carbapenem-resistant and OXA-23-producing Acinetobacter baumannii in multiple provinces of China. Int J Antimicrob Agents. 2013;42:322-8 pubmed publisher
    Carbapenem-resistant Acinetobacter baumannii has spread rapidly across China and is currently reported to be a worldwide nosocomial menace...
  71. García Quintanilla M, Pulido M, López Rojas R, Pachón J, McConnell M. Emerging therapies for multidrug resistant Acinetobacter baumannii. Trends Microbiol. 2013;21:157-63 pubmed publisher
    The global emergence of multidrug resistant Acinetobacter baumannii has reduced the number of clinically available antibiotics that retain activity against this pathogen...
  72. Tan S, Chua S, Liu Y, Høiby N, Andersen L, Givskov M, et al. Comparative genomic analysis of rapid evolution of an extreme-drug-resistant Acinetobacter baumannii clone. Genome Biol Evol. 2013;5:807-18 pubmed publisher
    ..Here, comparative genomics has been employed to analyze the rapid evolution of an EDR Acinetobacter baumannii clone from the intensive care unit (ICU) of Rigshospitalet at Copenhagen. Two resistant A...
  73. Ciftci I, Asik G, Karakece E, Oksüz L, Yağci S, Sesli Cetin E, et al. [Distribution of blaOXA genes in Acinetobacter baumannii strains: a multicenter study]. Mikrobiyol Bul. 2013;47:592-602 pubmed
    b>Acinetobacter baumannii is the most important agent of nosocomial infections within the Acinetobacter genus...
  74. Guzek A, Korzeniewski K, Nitsch Osuch A, Rybicki Z, Prokop E. In vitro sensitivity of Acinetobacter baumannii and Pseudomonas aeruginosa to carbapenems among intensive care unit patients. Adv Exp Med Biol. 2013;788:109-16 pubmed publisher
    b>Acinetobacter baumannii and Pseudomonas aeruginosa pathogens are the most common causes of fatal pneumonia among patients treated in Intensive Care Units (ICU)...